NL1014636C2 - Composition for treating repetitive strain injury comprises one or more B vitamins - Google Patents

Composition for treating repetitive strain injury comprises one or more B vitamins Download PDF

Info

Publication number
NL1014636C2
NL1014636C2 NL1014636A NL1014636A NL1014636C2 NL 1014636 C2 NL1014636 C2 NL 1014636C2 NL 1014636 A NL1014636 A NL 1014636A NL 1014636 A NL1014636 A NL 1014636A NL 1014636 C2 NL1014636 C2 NL 1014636C2
Authority
NL
Netherlands
Prior art keywords
vitamins
rsi
syndrome
composition
vitamin
Prior art date
Application number
NL1014636A
Other languages
Dutch (nl)
Other versions
NL1014636A1 (en
Inventor
Elisabeth Cornelia Gales Ubert
Original Assignee
Gales Anton
Elisabeth Cornelia Gales Ubert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gales Anton, Elisabeth Cornelia Gales Ubert filed Critical Gales Anton
Priority to NL1014636A priority Critical patent/NL1014636C2/en
Publication of NL1014636A1 publication Critical patent/NL1014636A1/en
Application granted granted Critical
Publication of NL1014636C2 publication Critical patent/NL1014636C2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51Thiamines, e.g. vitamin B1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composition comprising one or more B vitamins in amounts sufficient for the prevention or treatment of repetitive strain injury (RSI) syndrome is new. ACTIVITY : Analgesic. No suitable biological data given. MECHANISM OF ACTION : None given in the source material.

Description

- 1 - 5- 1 - 5

VitaminepreparaatVitamin preparation

De onderhavige uitvinding heeft betrekking op een 10 vitaminepreparaat dat geschikt is voor het behandelen en voorkomen van RSI-syndroom.The present invention relates to a vitamin preparation that is suitable for treating and preventing RSI syndrome.

In Nederland lijdt naar schatting 30 % van de beroepsbevolking aan RSI (Repetitive Strain Injury) en dreigen 400.000 beeldschermwerkers serieuze arbeidsproblemen te 15 krijgen t.g.v. het RSI-syndroom. Minstens 70% van beroepsmusici - wereldwijd - wordt ooit in zijn carrière belemmerd door klachten van houdings- en bewegingsapparaat. Ook andere beroepsgroepen, waaronder kappers, slagers, timmermannen, naaisters en metselaars krijgen RSI door herhaalde 20 hoge spierbelasting. Stress, werkdruk en een onregelmatige werktijden verhogen de risico's. Bij steeds meer mensen leidt RSI tot ziekteverzuim. Vrouwen (49%) hebben vaker klachten dan mannen (26%). Bij de beeldschermwerkers komen pijn in nek en schouders veel meer voor dan de 'muisarm' ; 25 die vooral op pijn en krachtverlies in arm en pols slaat. In de VS zijn de cijfers alarmerend. Tussen 1986 en 1993 groeide het aantal werknemers met klachten van de bovenste ledematen er met een factor drie. In Canada verdubbelde het aantal patiënten tussen 1986 en 1991. In Nederland krijgen 30 RSI en de werkdruk inmiddels de meeste aandacht in de discussie over arbeid en gezondheid. In het spraakgebruik is RSI inmiddels een ziekte. Maar in de officiële ziekteca-talogi (zoals de International Classification of Diseases, ICD) komt RSI niet voor. RSI is een paraplu waar veel al 35 lang bekende aandoeningen onder vallen. Het Amerikaanse Department of Health and Human Services concludeerde in een 1014636 - 2 - bibliografie uit 1995 dat al 165 ICD-codes zijn gebruikt in verband met RSI.In the Netherlands, an estimated 30% of the labor force suffers from RSI (Repetitive Strain Injury) and 400,000 screen workers risk serious work problems due to the RSI syndrome. At least 70% of professional musicians - worldwide - are once hampered in their career by posture and musculoskeletal complaints. Other professional groups, including hairdressers, butchers, carpenters, seamstresses and masons, also get RSI due to repeated high muscle loads. Stress, work pressure and irregular working hours increase the risks. RSI leads to sick leave for more and more people. Women (49%) have more complaints than men (26%). Pain in the neck and shoulders is much more common among computer workers than the 'mouse arm'; 25 that mainly refers to pain and loss of strength in the arm and wrist. The figures in the US are alarming. Between 1986 and 1993 the number of employees with complaints from the upper limbs grew by a factor of three. In Canada, the number of patients doubled between 1986 and 1991. In the Netherlands, 30 RSI and the workload now receive the most attention in the discussion about work and health. RSI has become a disease in speech. But RSI does not appear in the official disease catering logos (such as the International Classification of Diseases, ICD). RSI is an umbrella that includes many well-known disorders for 35 years. The US Department of Health and Human Services concluded in a 1014636-2 bibliography from 1995 that 165 ICD codes have already been used in connection with RSI.

Typerend voor het RSI-syndroom zijn de volgende anamnese gegevens: klachten ontstaan vaak langzaam bij 5 belastende werkzaamheden; klachten verdwijnen meestal in rust en in het weekeinde. Er zijn vaak klachten zonder klinisch aantoonbare defecten. Klachten gaan niet vanzelf over als men gewoon doorwerkt, maar worden meestal erger bij doorwerken. De klachten zijn belastingafhankelijk en 10 wisselen soms van locatie en lichaamszijde. De meest voorkomende symptomen/subsyndromen van RSI zijn: hoofd pi jn/vermoeidheid; pijn en stijfheid in rug, nek, schouder (s) en tussen de schouderbladen; pijn en stijfheid in arm, pols en hand; onduidelijke diagnoses 'tennis- en/of 15 golferselleboog'; slijmbeursontstekingen aan schouder of elleboog; tintelingen / branderig /'raar'gevoel in (onder) arm, pols en hand; verlies van kracht in arm, pols en hand/zwaar gevoel in de armen; Carpaal Tunnel Syndroom.The following anamnesis data is typical of RSI syndrome: complaints often arise slowly during 5 burdensome activities; complaints usually disappear at rest and during the weekend. There are often complaints without clinically demonstrable defects. Complaints do not pass automatically if people continue to work, but usually get worse when working. The complaints are tax-dependent and 10 sometimes change location and body side. The most common symptoms / sub-syndromes of RSI are: head pain / fatigue; pain and stiffness in the back, neck, shoulder (s) and between the shoulder blades; pain and stiffness in arm, wrist and hand; unclear diagnoses 'tennis and / or 15 golfers elbow'; Bursa inflammation on shoulder or elbow; tingling / burning / 'weird' feeling in (lower) arm, wrist and hand; loss of strength in arm, wrist and hand / heavy feeling in the arms; Carpal tunnel syndrome.

20 Stadia20 Stages

De (RSI) klachten kennen drie stadia, oplopend in ernst:The (RSI) complaints have three stages, increasing in severity:

Stadixun 1: lichte pijn en/of stijfheid in nek/schouder of tussen de schouderbladen, vaak samen met 25 tintelingen, stijfheid of 'vreemd' gevoel in de (onder)ar-men/polsen/handen. De klachten treden op na langdurige belasting en gaan in rust meestal weer weg.Stadixun 1: slight pain and / or stiffness in the neck / shoulder or between the shoulder blades, often together with tingling, stiffness or 'strange' feeling in the (lower) arms / wrists / hands. The complaints occur after a long period of stress and usually go away at rest.

Stadivun 2. - de klachten treden steeds sneller op 30 en blijven steeds langer aanwezig na het stoppen van de belastende bezigheden. De relatie tussen inspanning en klachten wordt minder duidelijk. Bij andere bezigheden in het dagelijks leven treden de klachten vaker op. De klachten worden minder nauwkeurig te lokaliseren en er treedt 35 krachtsverlies in de handen en een 'zwaar' gevoel in de armen op.Stadivun 2. - the complaints occur more and more quickly and continue to be present longer after stopping the incriminating activities. The relationship between effort and complaints becomes less clear. With other activities in daily life, the complaints occur more often. The complaints become less accurate to locate and there is a loss of strength in the hands and a 'heavy' feeling in the arms.

1014636 4 - 3 -1014636 4 - 3 -

Stadium 3: er is nu sprake van continue pijn die bij elke belastende bezigheid erger wordt, 's Nachts wordt de patiënt soms wakker van de klachten. Werken en andere dagelijkse bezigheden zijn nauwelijks uitvoerbaar zonder 5 klachten. Een veel beschreven symptoom is ook vermoeidheid.Stage 3: there is now continuous pain that gets worse with every incriminating activity, the patient sometimes wakes up during the night. Working and other daily activities are hardly feasible without 5 complaints. Fatigue is also a commonly described symptom.

Eén van de verklaringstheorieën voor het RSI-syndroom luidt als volgt:One of the explanation theories for RSI syndrome is as follows:

De werkplek is oorzaak van een langdurige laagsta-tische spierbelasting in een ongunstige houding waardoor 10 rug-/nek-/schouderspieren continu aangespannen zijn. Er ontstaat een verstoorde energiehuishouding in de nek/schou-ders en beide armen, wat wil zeggen dat voedingsstoffen niet aangevoerd kunnen worden en dat afvalstoffen niet afgevoerd kunnen worden. Als de werker vervolgens van 15 zijn/haar kwetsbare armen een zeer eenzijdige hoog energetische belasting vraagt (denk aan typen, kassawerk of inpakwerk aan de lopende band), ontstaat op den duur schade aan spieren/pezen van de armen. Dit gaat vaak gepaard met bindweefselvorming (littekens). In veel gevallen ontstaat 20 op de overgang van stadium 2 naar stadium 3 een overgevoeligheid van de pijnbanen in het hele nek/schouder/arm/hand complex. Deze overgevoeligheid gaat via dwarsverbindingen in het ruggenmerg ook naar de andere lichaamszijde, hetgeen klachten aan de niet-dominante zijde kan verklaren. Stress 25 lijkt in veel gevallen een versterkende factor.The workplace is the cause of a long-term low-static muscle load in an unfavorable position, whereby 10 back / neck / shoulder muscles are constantly contracted. A disturbed energy balance arises in the neck / shoulders and both arms, which means that nutrients cannot be supplied and that waste cannot be removed. If the worker then demands a very one-sided high energy load from his / her vulnerable arms (such as typing, cash register work or packing on the conveyor belt), in the long term damage to muscles / tendons of the arms will occur. This is often accompanied by connective tissue formation (scars). In many cases, on the transition from stage 2 to stage 3, there is a hypersensitivity of the pain tracts throughout the neck / shoulder / arm / hand complex. This hypersensitivity also goes via cross connections in the spinal cord to the other body side, which may explain complaints on the non-dominant side. In many cases, stress 25 seems to be a reinforcing factor.

Gevonden is nu dat door het toedienen van een preparaat dat één of meer vitaminen B en eventueel andere vitaminen bevat aan personen die lijden aan het RSI-syndroom, de bij het RSI-syndroom optredende verschijnselen 30 aanzienlijk verlicht of zelfs geheel weggenomen worden.It has now been found that by administering a preparation containing one or more vitamins B and possibly other vitamins to persons suffering from the RSI syndrome, the symptoms occurring with the RSI syndrome are considerably alleviated or even completely eliminated.

Derhalve voorziet de uitvinding in het gebruik van een vitamine B of een preparaat dat één of meer vitaminen B bevat, voor het bereiden van een geneesmiddel voor het voorkomen of behandelen van het RSI-syndroom.Therefore, the invention provides for the use of a vitamin B or a preparation containing one or more vitamins B for the manufacture of a medicament for preventing or treating the RSI syndrome.

35 De uitvinding voorziet verder in een preparaat dat één of meer vitaminen B bevat in hoeveelheden die voldoende zijn voor het behandelen of voorkomen van het RSI-syndroom.The invention further provides a preparation containing one or more vitamins B in amounts sufficient to treat or prevent RSI syndrome.

1014636 4 - 4 -1014636 4 - 4 -

Het preparaat volgens de uitvinding bevat in het bijzonder de vitaminen BI, B2, B3, B5, B6, B7 en B12 in hoeveelheden die voldoende zijn voor het behandelen of voorkomen van het RSI-syndroom.The preparation according to the invention contains in particular the vitamins B1, B2, B3, B5, B6, B7 and B12 in amounts sufficient to treat or prevent RSI syndrome.

5 Personen die leden aan het RSI-syndroom en die het preparaat volgens de uitvinding oraal innamen, hadden na korte tijd aanzienlijk minder of in het geheel geen RSI-verschijnselen meer. Het preparaat van de uitvinding is ondermeer tegen de volgende met RSI verbonden aandoeningen 10 effectief gebleken: "rotator cuff syndroom", epicondylitis lateratis ("tenniselleboog") en epicondylitis medialis ("golferselleboog").Persons who suffered from the RSI syndrome and who took the preparation according to the invention orally, after a short time had considerably less or no longer any RSI symptoms. The preparation of the invention has been found to be effective, inter alia, against the following disorders associated with RSI: "rotator cuff syndrome", epicondylitis lateratis ("tennis elbow") and epicondylitis medialis ("golfer's elbow").

Het preparaat volgens de uitvinding kan elke geschikte farmaceutische toedieningsvorm hebben. Een 15 geschikte vorm voor orale toediening is bijvoorbeeld een tablet of een capsule.The composition according to the invention can be in any suitable pharmaceutical dosage form. A suitable form for oral administration is, for example, a tablet or a capsule.

Het preparaat kan naast de vitaminen B, de andere vitaminen en verdere werkzame stoffen de gebruikelijke farmaceutische hulpstoffen zoals dragers/verdunningsmiddelen, 20 vulstoffen, verdikkingsmiddelen, destintegreermiddelen, tabletteerhulpstoffen, kleur- en smaakstoffen etc. bevatten .The preparation may contain, in addition to vitamins B, the other vitamins and further active ingredients, the usual pharmaceutical auxiliaries such as carriers / diluents, fillers, thickeners, destintegrating agents, tableting aids, coloring and flavoring agents etc.

Voorbeeld 25 Een oraal preparaat met de in tabel 1 gegeven samenstelling van werkzame stoffen werd bereid en een- of tweemaal daags aan personen die leden aan het RSI-syndroom toegediend. De verkregen resultaten zijn samengevat in tabel 2.Example 25 An oral preparation with the active ingredient composition given in Table 1 was prepared and administered once or twice daily to persons suffering from RSI syndrome. The results obtained are summarized in Table 2.

30 1014636 - 5 -30 1014636 - 5 -

Tabel 1 Samenstelling van de werkzame stoffen in het vitaminepreparaatTable 1 Composition of the active substances in the vitamin preparation

Eenheid mg EenheidUnit mg Unit

Vitamine A Retinol 150 5 Vitamine BI thiaminemononi- 15 traatVitamin A Retinol 150 5 Vitamin B1 thiamine mononitrate

Vitamine B2 . riboflavine 16Vitamin B2. riboflavin 16

Vitamine B3 nicotinamide 25Vitamin B3 nicotinamide 25

Vitamine B5 calciumpantothe- 25 10 naatVitamin B5 calcium pantothenate

Vitamine B6 pyridoxinehydro- 5,3 chlorideVitamin B6 pyridoxine hydrochloride 5.3

Vitamine B7 biotine 25Vitamin B7 biotin 25

Vitamine B12 cyanocobalamine 1,7 15 Vitamine C ascorbinezuur 20Vitamin B12 cyanocobalamin 1.7 15 Vitamin C ascorbic acid 20

Vitamine D cholecaferol 1Vitamin D cholecaferol 1

Vitamine E D-alfa tocoferol 2Vitamin E D-alpha tocopherol 2

Inositol 5 p-aminoben- 40 20 zoëzuurInositol 5 p-aminobenzoic acid

Calcium 215Calcium 215

Fosfor 200'Phosphorus 200 '

Kalium 640 25 Natrium. 125Potassium 640 Sodium. 125

Magnesium 35 IJzer 3Magnesium 35 Iron 3

Mangaan 0,2Manganese 0.2

Zink 2 30 Jodium 2 5Zinc 2 30 Iodine 2 5

Seleen 10Selenium 10

Koper 0,3 n 1 KQe - 6 -Copper 0.3 n 1 KQe - 6 -

Tabel 2 Resultaten ·Table 2 Results ·

Proef- Man (M) Leef- Lengte RSI- Periode Resul- perso- Vrouw tijd periode stadium innemen taat nen (V) jaar RSI- middeel klach- (weken) ten (maanden) 5 Proef- V 22 3 1 31 Genezen persoon 1Test Male (M) Live Length of RSI - Period Result - Female time period stage taking (V) years RSI - middle part complaints (weeks) (months) 5 Test V 22 3 1 31 Healed person 1

Proef- M 50 5 1 121 Genezen persoon 10 2Test M 50 5 1 121 Healed person 10 2

Proef- M 42 36 3 32> Genezen persoon 3Test M 42 36 3 32> Healed Person 3

Proef- M 29 24 3 2S> Aan- 15 persoon zien- 4 lijke verbe teringTest M 29 24 3 2S> Personal improvement

Proef- V 28 24 3 221 Aan- persoon zien- 5 lijke verbe tering 20 Proef- M 50 40 3 22) Aan- persoon zien- 6 lijke verbe tering 1014636 behandeling beëindigd 25 21 behandeling wordt voortgezetTest V 28 24 3 221 Personal significant improvement 20 Test M 50 40 3 22) Personal significant improvement 1014636 treatment terminated 25 21 treatment continued

Claims (4)

1. Gebruik van een vitamine B of een preparaat dat 10 één of meer vitaminen B bevat, voor het bereiden van een geneesmiddel voor het voorkomen of behandelen van het RSI-syndroom.Use of a vitamin B or a preparation containing one or more vitamins B for the preparation of a medicament for the prevention or treatment of the RSI syndrome. 2. Preparaat dat één of meer vitaminen B bevat in hoeveelheden die voldoende zijn voor het behandelen of 15 voorkomen van het RSI-syndroom.2. A preparation containing one or more vitamins B in amounts sufficient to treat or prevent RSI syndrome. 3. Preparaat voor het behandelen of voorkomen van het RSI-syndroom, dat vitamines BI, B2, B3, B5, B6, B7 en B12 bevat in hoeveelheden die voldoende zijn voor het behandelen of voorkomen van het RSI-syndroom.3. A preparation for treating or preventing RSI syndrome, which contains vitamins B1, B2, B3, B5, B6, B7 and B12 in amounts sufficient to treat or prevent RSI syndrome. 4. Preparaat volgens conclusie 3, dat verder vitaminen A, C, D en E, inositol, p-aminobenzoëzuur, calcium, fosfor, kalium, natrium, magnesium, ijzer, mangaan, zink, jodium, seleen en koper bevat. 1 Π 1 3RThe composition of claim 3, further comprising vitamins A, C, D, and E, inositol, p-aminobenzoic acid, calcium, phosphorus, potassium, sodium, magnesium, iron, manganese, zinc, iodine, selenium, and copper. 1 Π 1 3R
NL1014636A 2000-03-14 2000-03-14 Composition for treating repetitive strain injury comprises one or more B vitamins NL1014636C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NL1014636A NL1014636C2 (en) 2000-03-14 2000-03-14 Composition for treating repetitive strain injury comprises one or more B vitamins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1014636 2000-03-14
NL1014636A NL1014636C2 (en) 2000-03-14 2000-03-14 Composition for treating repetitive strain injury comprises one or more B vitamins

Publications (2)

Publication Number Publication Date
NL1014636A1 NL1014636A1 (en) 2001-09-17
NL1014636C2 true NL1014636C2 (en) 2002-07-16

Family

ID=19770994

Family Applications (1)

Application Number Title Priority Date Filing Date
NL1014636A NL1014636C2 (en) 2000-03-14 2000-03-14 Composition for treating repetitive strain injury comprises one or more B vitamins

Country Status (1)

Country Link
NL (1) NL1014636C2 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326034A2 (en) * 1988-01-28 1989-08-02 Peter Dr. Költringer Combination for the treatment of nervous cells and fibers illnesses and disorders
DE4110087A1 (en) * 1991-03-27 1992-10-01 Fritz Dr Woerwag Benfotiamine-contg. pharmaceutical for topical use - is for treating e.g. rheumatic disorders, sciatica, lumbago, migraine etc. and other disorders beneficially affected by vitamin=B
WO1994000135A1 (en) * 1992-06-30 1994-01-06 Shapiro Howard K Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases
US5514382A (en) * 1994-10-17 1996-05-07 Sultenfuss; Sherry Daily vitamin and mineral supplement for women
US5612382A (en) * 1994-07-15 1997-03-18 Frances B. Fike Composition for percutaneous absorption of pharmaceutically active ingredients
WO1997016079A1 (en) * 1995-10-27 1997-05-09 Societe Des Produits Nestle S.A. Nutritional support of paediatric patients
WO2001019359A2 (en) * 1999-09-16 2001-03-22 Britannia Pharmaceuticals Limited Medicaments containing pantothenic acid for the treatment of inflammatory joint disease
WO2001091766A2 (en) * 2000-06-01 2001-12-06 Theralife, Inc. Compositions for treating hand and wrist discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326034A2 (en) * 1988-01-28 1989-08-02 Peter Dr. Költringer Combination for the treatment of nervous cells and fibers illnesses and disorders
DE4110087A1 (en) * 1991-03-27 1992-10-01 Fritz Dr Woerwag Benfotiamine-contg. pharmaceutical for topical use - is for treating e.g. rheumatic disorders, sciatica, lumbago, migraine etc. and other disorders beneficially affected by vitamin=B
WO1994000135A1 (en) * 1992-06-30 1994-01-06 Shapiro Howard K Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases
US5612382A (en) * 1994-07-15 1997-03-18 Frances B. Fike Composition for percutaneous absorption of pharmaceutically active ingredients
US5514382A (en) * 1994-10-17 1996-05-07 Sultenfuss; Sherry Daily vitamin and mineral supplement for women
WO1997016079A1 (en) * 1995-10-27 1997-05-09 Societe Des Produits Nestle S.A. Nutritional support of paediatric patients
WO2001019359A2 (en) * 1999-09-16 2001-03-22 Britannia Pharmaceuticals Limited Medicaments containing pantothenic acid for the treatment of inflammatory joint disease
WO2001091766A2 (en) * 2000-06-01 2001-12-06 Theralife, Inc. Compositions for treating hand and wrist discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALLEN-TAYLOR J.D.: "Silicon Vitamins", METRO, 28 January 1999 (1999-01-28) - 3 February 1999 (1999-02-03), pages 1 - 5, XP002190200, Retrieved from the Internet <URL:https://www.metroactive/com/papers/metro/01.28.99/slices-9904.html> [retrieved on 20020214] *
FOLKERS K ET AL: "SUCCESSFUL THERAPY WITH VITAMIN B-6 AND VITAMIN B-2 OF THE CARPAL TUNNEL SYNDROME AND NEED FOR DETERMINATION OF THE RDAS FOR VITAMINS B-6 AND B-2 FOR DISEASE STATES", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, pages 295 - 301, XP008000385, ISSN: 0077-8923 *
KASDAN M L ET AL: "CARPAL TUNNEL SYNDROME AND VITAMIN B-6", PLASTIC AND RECONSTRUCTIVE SURGERY, vol. 79, no. 3, 1987, pages 456 - 459, XP008000386, ISSN: 0032-1052 *

Also Published As

Publication number Publication date
NL1014636A1 (en) 2001-09-17

Similar Documents

Publication Publication Date Title
Cutter et al. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial
Mary Collins et al. Putting Evidence Into Practice®: Evidence-based interventions for chemotherapy-induced peripheral neuropathy
Jamshidovich HEPTRAL IS USED IN LIVER DISEASES
Francisco et al. Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study
Messier et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study
Ellis et al. Clinical results of a cross-over treatment with pyridoxine and placebo of the carpal tunnel syndrome
Karbwang et al. Pharmacokinetics of mefloquine alone or in combination with artesunate.
Fenichel et al. Clinical investigation in Duchenne muscular dystrophy: penicillamine and vitamin E
Takala Static muscular load, an increasing hazard in modern information technology
Mock et al. Current management of fatigue and anemia in patients with cancer
Shay Dental management considerations for institutionalized geriatric patients
HOCHBERG Auranofin or D-penicillamine in the treatment of rheumatoid arthritis
NL1014636C2 (en) Composition for treating repetitive strain injury comprises one or more B vitamins
Jacobsson et al. Evaluation of a structured multidisciplinary day care program in rheumatoid arthritis: a similar effect in newly diagnosed and long-standing disease
Ferguson et al. Hydroxyurea treatment of sickle cell anemia in hospital‐based practices
Le Riche et al. A long-acting appetite suppressant drug studied for 24 weeks in both continuous and sequential administration.
AIRD Trypan Red Therapy of Amyotrophic Lateral Sclerosis: Preliminary Report
De Boer et al. Treatment of recurrent posterior dislocation of the shoulder in cerebral palsy by injection with botulinum toxin A into the M. subscapularis
Stone et al. VITAMIN B AND E THERAPY IN TABES DORSALIS:(Preliminary Report on the Use of Wheat Germ Oil, Vitamin B Complex and Intraspinal Administration of Thiamin Chloride)
Shafiq et al. Effect of Specific Stabilization Exercise Along with Muscle Relaxation Technique to Treat Lumbopelvic Pain During Pregnancy: Muscle Relaxation Technique to Treat Lumbopelvic Pain During Pregnancy
Jerome Alternative treatment modalities in human immunodeficiency virus/acquired immune deficiency syndrome
Brown Blood-pressure-lowering treatment
Jackson Phen/Fen
Zizic et al. The treatment of rheumatoid arthritis of the hand with pulsed electrical fields
Brinkhaus Latest Publications You Should Not Miss

Legal Events

Date Code Title Description
AD1A A request for search or an international type search has been filed
RD2N Patents in respect of which a decision has been taken or a report has been made (novelty report)

Effective date: 20020312

PD2B A search report has been drawn up
VD1 Lapsed due to non-payment of the annual fee

Effective date: 20081001